Drug Profile


Alternative Names: 3K3A-activated protein C; 3K3A-APC non-anticoagulant mutant - ZZ Biotech; Activated protein C analogue with reduced anticoagulant activity -ZZ Biotech; Genetically engineered variant of recombinant human wild-type activated Protein C (APC) - ZZ Biotech; Recombinant variant of human activated protein C (3K3A-APC)

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Socratech; The Scripps Research Institute; University of Southern California
  • Developer The Scripps Research Institute; University of Southern California; ZZ Biotech
  • Class Antithrombotics; Blood proteins; Enzyme precursors; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Activated protein C receptor modulators; Factor V inhibitors; Factor VIII inhibitors; PAR 1 receptor modulators; PAR-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Stroke

Highest Development Phases

  • Phase II Stroke
  • Preclinical Amyotrophic lateral sclerosis; Neurological disorders; Septic shock

Most Recent Events

  • 08 Dec 2016 3K3A-APC is still in phase II trials for Stroke in USA (IV)
  • 01 Oct 2014 Phase-II clinical trials in Stroke in USA (IV) (NCT02222714)
  • 22 Apr 2014 ZZ Biotech receives NeuroNEXT Infrastructure Resource Access award and Cedars-Sinai receives a $US8 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) for 3K3A APC development in Stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top